Le Lézard
Classified in: Health
Subject: FDA

Amerigen Announces U.S. FDA Approval For Generic Penicillamine 250 mg Capsules


LYNDHURST, N.J., May 8, 2019 /PRNewswire/ -- Amerigen Pharmaceuticals Limited ("Amerigen") today announced that Amerigen's Abbreviated New Drug Application ("ANDA") for Penicillamine Capsules USP 250 mg has received final approval from the U.S. Food and Drug Administration. This is the first such ANDA to be approved as a generic equivalent to Bausch Heath's Cuprimine®. The finished product is manufactured for Amerigen in the U.S. where it has already been launched by Amerigen's affiliate, Amerigen Pharmaceuticals, Inc.

Penicillamine Capsules USP are indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.

John Lowry, Amerigen's President and CEO, commented "We are delighted to launch this first generic of Penicillamine Capsules. This is Amerigen's ninth U.S. product launch and the fourth time we have brought a first generic to market, with important savings for the American healthcare system."

About Amerigen

Amerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the U.S. and China. The group is controlled by Amerigen Pharmaceuticals Limited. The U.S. regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc., based in Lyndhurst, NJ. The group's Chinese subsidiary, Suzhou Amerigen Pharmaceutical Company Limited, is located in Suzhou, Jiangsu Province.

The group has products on the market currently in both the U.S. and China plus an active portfolio of products under development, filed, or intended for filing, as ANDA's with the U.S. FDA and the Chinese NMPA. Amerigen's focus is orally delivered products that are challenging to develop, require specialized technologies or high containment to manufacture, and present complex regulatory and intellectual property obstacles to bring to market. All Amerigen's products are developed and manufactured by the company or its partners around the world to meet the highest quality standards, including the U.S. FDA.

SOURCE Amerigen Pharmaceuticals


These press releases may also interest you

at 09:05
QuantHealth, an AI-powered clinical trial design company, today announced the formation of its inaugural Advisory Board. Founding members Michel Vounatsos, former CEO of Biogen, Rob Scott, former Chief Medical Officer for AbbVie, and Christian Hein,...

at 09:05
ValGenesis, Inc., the market leader in enterprise validation lifecycle management systems (VLMS), today announced that a leading global biotechnology company selected ValGenesis iRisk to digitalize the quality risk management processes across its...

at 09:03
Vero AI, a first-of-its-kind analytical engine and scoreboard that helps enterprises fully harness the potential of advanced technology including artificial intelligence while minimizing risk, announced the findings of its inaugural "Generating...

at 09:00
ROYAL CANIN® U.S., a division of Mars, Incorporated and leader in pet health nutrition, has announced an expansion to its Veterinary Gastrointestinal (GI) portfolio. Gastrointestinal issues are the 3rd and 4th most common issue in cats and dogs that...

at 09:00
Peoplehood, a first-of-its-kind social wellness company created by the founders of SoulCycle, today announced the launch of Peoplehood @Work. The @Work program consists of a series of facilitated, interactive team conversations, customized for each...

at 09:00
Addressing cultural friction within operating rooms has emerged as a critical imperative for healthcare institutions nationwide. Surgical Directions sheds light on the detrimental effects of cultural discord, including high clinician and staff...



News published on and distributed by: